Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions

S Hennessy; C E Leonard; J J Gagne; J H Flory; X Han; C M Brensinger; W B Bilker

doi:10.1002/cpt.277

Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions

Clin Pharmacol Ther. 2016 Jan;99(1):92-100. doi: 10.1002/cpt.277. Epub 2015 Nov 23.

Authors

S Hennessy¹, C E Leonard¹, J J Gagne², J H Flory^{1

3

4}, X Han¹, C M Brensinger¹, W B Bilker¹

Affiliations

¹ Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, and Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
² Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Division of Comparative Effectiveness and Outcomes Research, Department of Healthcare Research and Policy, Weill Cornell Medical College, New York, New York, USA.
⁴ Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

PMID: 26479278
PMCID: PMC4720556
DOI: 10.1002/cpt.277

Abstract

A drug-drug interaction (DDI) occurs when one or more drugs affect the pharmacokinetics (the body's effect on the drug) and/or pharmacodynamics (the drug's effect on the body) of one or more other drugs. Pharmacoepidemiologic studies are the principal way of studying the health effects of potential DDIs. This article discusses aspects of pharmacoepidemiologic research designs that are particularly salient to the design and interpretation of pharmacoepidemiologic studies of DDIs.

Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding